UST claims its PBV process technology makes it possible to achieve higher yields after drying and better stability during storage at ambient or even higher temperatures (including 37°C or higher) than is currently possible with conventional techniques such as freeze drying or spray drying.
Under the agreement, Enterologics will fund the development program and UST will work on the optimization of pharmaceutical-grade probiotic dosage form with extended shelf-life and viability at ambient temperatures.
Enterologics president Bob Hoerr said they believe that UST’s vitrification technology, shelf-stable dosage form will enable them to meet a key goal in the commercialization program to develop probiotic products as approved biologic drugs for gastrointestinal diseases.
UST president and founder Victor Bronshtein said based on their research, their proprietary dosage format should enable probiotics to meet ambient (from -20°C to + 37°C) temperature shelf-life standards for a pharmaceutical product.